Rznomics' RZ-001 Gets EU Orphan Drug Designation for Glioma
Rznomics has received European Commission (EC) orphan medicinal product designation for RZ-001, supporting its development as a potential treatment for glioma.
Dr. Seong-Wook Lee | 22/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy